Table 1:
Clinical Characteristics of ATTR-CA with comparing patients without AF with patients with AF, along with comparing patients treated with warfarin with patients treated with NOACs
| Baseline Characteristics for Patients with ATTR-CA Comparing Atrial Fibrillation vs No Atrial Fibrillation and Warfarin vs. NOACs | ||||||
|---|---|---|---|---|---|---|
| Arrhythmias | Atrial Fibrillation Treatment | |||||
| Atrial Fibrillation | No Atrial Fibrillation | p Value | Warfarin | NOACs | p Value | |
| (n=217) | (n=73) | (n=78) | (n=116) | |||
| Age | 75.0 +/− 8.1 | 71.0 +/− 9.8 | < 0.01 | 75.2+/−8.3 | 75.3 +/− 7.6 | 0.97 |
| Gender (Male) | 194 (89.4%) | 54 (73.9%) | < 0.01 | 69 (88.5%) | 103 (88.8%) | 0.94 |
| Ethnicity | < 0.01 | 0.17 | ||||
| Caucasian | 165 | 42 | 58 | 92 | ||
| African | 42 | 30 | 18 | 17 | ||
| American | ||||||
| Genotype | < 0.01 | 0.17 | ||||
| Wildtype | 169 | 28 | 59 | 97 | ||
| Hereditary | 48 | 44 | 19 | 19 | ||
| A120S | 1 | 0 | 0 | 1 | ||
| Ala117Ser | 0 | 1 | 0 | 0 | ||
| Asp38Ala | 1 | 0 | 1 | 0 | ||
| Asp70Lys | 1 | 0 | 0 | 1 | ||
| Gln89 | 0 | 1 | 0 | 0 | ||
| Phe64Leu | 1 | 2 | 1 | 0 | ||
| Ser23Asn | 0 | 1 | 0 | 0 | ||
| Thr35 | 1 | 0 | 1 | 0 | ||
| Thr59Lys | 0 | 2 | 0 | 0 | ||
| Thr60Ala | 5 | 6 | 1 | 4 | ||
| Thr79Lys | 1 | 0 | 0 | 1 | ||
| V122I | 38 | 30 | 21 | 11 | ||
| Val30Met | 1 | 2 | 1 | 0 | ||
| BMI | 26.6 +/−3.8 | 25.6+/−3.9 | 0.05 | 26.1 +/−3.4 | 27.1+/−4.2 | 0.09 |
| Hypertension | 118 (54.3%) | 42 (57.5%) | 0.63 | 38 (48.7%) | 61 (52.6%) | 0.59 |
| Diabetes | 28 (12.9%) | 8 (10.9%) | 0.66 | 7 (9.0%) | 18 (15.5%) | 0.18 |
| Prior embolism | 35 (16.1%) | 7 (9.6%) | 0.17 | 16 (20.5%) | 14 (12.1%) | 0.11 |
| CKD Stage IV-V | 15 (6.9%) | 1 (1.4%) | 0.08 | 7 (9.0%) | 6 (5.2%) | 0.38 |
| Renally dosed NOACs | - | - | - | 27 (23.3%) | ||
| Aspirin | 73 (33.6%) | 37 (50.7%) | 0.01 | 29 (37.2%) | 36 (31.0%) | 0.44 |
| P2Y12 Inhibitors | 14 (6.5%) | 6 (8.2%) | 0.60 | 9 (11.5%) | 5 (4.3%) | 0.09 |
| Diflunisal | 31 (14.3%) | 19 (26.0%) | 0.03 | 10 (4.6%) | 17 (14.7%) | 0.83 |
| Tafamadis | 17 (7.8%) | 1 (1.4%) | 0.05 | 5 (6.4%) | 10 (8.6%) | 0.57 |
| CHA2DS2-VASc | 3.7 +/− 1.2 | 3.5 +/− 1.5 | 0.15 | 3.7+/− 1.2 | 3.8+/− 1.2 | 0.8 |
| HAS-BLED | 2.6 +/− 0.9 | 1.9 +/− 1.0 | <0.01 | 3.1 +/− 0.9 | 2.5 +/− 0.7 | < 0.01 |
AF= atrial fibrillation, NOACs = novel oral anticoagulants, BMI = body mass index, CKD = chronic kidney disease